O.B.System Inc.
TTSE:55763,210.00
JPY
-225.00
(-6.55%)
ISIN
JP3173250006
Return %
Stock
S&P 500
1Y
3.05
14.20
3Y
64.36
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Toshio Toyoda
- Full Time Employees
- 624
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Urban Ace Kitahama Building Osaka Japan 541-0046
- IPO Date
- Jun 21, 2023
- Website
- obs.co.jp
- Similar Companies
- Business
- O.B.System Inc. is a Japan-based company specializing in system integration and development primarily for medical and clinical testing equipment, laboratory information systems, and diagnostic solutions. The company offers a comprehensive range of products and services including clinical chemistry automated analyzers, immunoassay systems, hematology analyzers, microbiology and molecular diagnostics equipment, point of care testing solutions, and laboratory information management systems. It also provides sales and maintenance of medical analyzers, biophysical chemistry instruments, research reagents, pathological systems, remote diagnostic imaging systems, image analysis systems, and life-saving/intraoperative diagnostic equipment. O.B.System serves healthcare providers, clinical laboratories, and medical institutions in over 80 countries worldwide. Founded in 1976 and headquartered in Tokyo, Japan, the company continues to expand its footprint in the global healthcare diagnostics market. Recent major developments include the acquisition of Greencat Co., Ltd. in March 2025, which reflects O.B.System’s strategic move to strengthen its technological capabilities and expand its market presence. The company has also reported ongoing steady demand in its clinical testing and system development segments, with efforts to optimize pricing and supply chain activities. These changes align with O.B.System’s focus on enhancing its integrated system solutions and service offerings to support evolving clinical testing needs and laboratory automation technologies on a global scale. The company continues to invest in scalable lab automation, clinical informatics, and comprehensive lab performance optimization services to accelerate care delivery across its broad customer base. O.B.System operates mainly in the healthcare diagnostics and medical equipment segments, targeting clinical labs, hospitals, and research institutions. The company’s product portfolio emphasizes precision diagnostic tools and information systems to improve laboratory workflow and diagnostic accuracy. Headquartered in Tokyo, O.B.System leverages global distribution channels and partnerships to maintain a competitive position in the international markets it serves. The strategic acquisition of Greencat Co., Ltd. marks a significant enhancement in its technological capabilities and service scope, supporting sustained business growth and innovation in clinical diagnostics.